Immunization Newsbriefs
Link to Main Page
  Back Search the Site Send Your Feedbck  
Immunization Newsbriefs
Read Current Issue Online
Search Newsbriefs Archives
Subscribe to Email Online
Unsubscribe from Email Online
About NNii
Vaccine Information
Health Professionals
Policy Makers
Read Current Newsbriefs

VaxGen Wins License for Anthrax Vaccine
Wall Street Journal; C11


A development agreement between the U.S. Army Medical Research Institute of Infectious Diseases and VaxGen gives VaxGen worldwide rights to the development and marketing of the Institute's recombinant anthrax vaccine candidate. In exchange, the Institute will receive certain fees and royalties. The vaccine, known as rPA102, is currently undergoing the first phase of clinical testing. VaxGen is funding the development with a three-year, $80.3 million contract from the National Institute of Allergy and Infectious Diseases.

© Copyright National Network for Immunization Information. The information contained in the National Network for Immunization Information Web site should not be used as a substitute for the medical care and advice of your health care provider. There may be variations in treatment that your health care provider may recommend based on individual facts and circumstances.